Genentech Inc Recall: Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carto
Genentech Inc Recall: Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carto is one of 9,000 recalls in the RecallGuard dataset. Key details — Recalling firm: Genentech Inc; Product: Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial and One Susvi
| Recalling firm | Genentech Inc |
|---|---|
| Product | Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial and One Susvimo initial fill needle, NDC 50242-078-55; and b) carton labeled as Susvimo Ocular Implant with Insertion Tool Assembly, containing One carrier with implant and One insertion Tool, UDI 81004259001, GTIN 00810042590014, Rx only, Genentech, Inc., A Member of the Roche Group, South San Francisco, CA 94080-4990. |
| Reason for recall | Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning. |
| Classification | Class III (least serious — unlikely to cause adverse health consequences) |
| Status | Terminated |
| Distribution | Nationwide in the USA |
| Recall initiated | 20221018 |
| Recall number | D-0025-2023 |
| Category | drug |
| State | CA |
| Country | United States |
$29/mo
Try RecallGuard →